Rime

Quick links to important sections

Rime

Method of action: Bactericidal

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rime

What is Rime? Overview and Quick Facts

Property Description
Active ingredient Cefpirome
Form Sterile powder for injection/infusion
Pharmacological class Fourth-generation Cephalosporin, beta-Lactam antibiotic
Common purpose Treatment of systemic bacterial infections
Origin Synthetic

Rime (Cefpirome): A Fourth-Generation Cephalosporin

Rime is the medicinal entity whose active ingredient is Cefpirome, classified as a powerful, synthetic, and prescription-only antibacterial agent. Cefpirome belongs to the beta-Lactam antibiotic family and is specifically recognized as a fourth-generation cephalosporin, representing an advanced development within this major class of infection-fighting drugs. Pharmacological studies have widely supported the drug's utility in treating serious, systemic infections. This advanced classification ensures it is a robust therapeutic option, primarily reserved for treating serious, susceptible bacterial infections, such as severe respiratory or urinary tract infections, when administered in a clinical setting.

Composition, Form, and General Purpose

The medication is composed of the single active ingredient, Cefpirome, typically supplied as Cefpirome sulfate or Cefpirome pentahydrate, presented in the form of a sterile powder for solution for injection. Its synthetic origin allows for predictable quality and stability, a necessity for critical care medicine. As a parenteral drug, it requires reconstitution with a sterile solution immediately prior to intravenous administration. The general purpose of this therapy is to exert a bactericidal effect, meaning it actively kills the bacteria that cause illness by disrupting their structural integrity. Clinically, Cefpirome is recognized for its strong activity against common hospital-acquired pathogens, including Pseudomonas aeruginosa.

How Cefpirome Differentiates from Older Antibiotics

Cefpirome differentiates itself from many older or first-generation antibiotics by demonstrating enhanced stability against degradation by bacterial defense enzymes, known as beta-Lactamases. The design of this fourth-generation agent confers significant resilience against common bacterial resistance mechanisms, a feature that distinguishes it from predecessor compounds. This superior stability, coupled with its broad-spectrum capability, is why this advanced synthetic agent is considered a high-value resource for medical professionals when managing complicated infections, particularly those where bacterial resistance to more conventional antimicrobial agents presents a major clinical challenge.

What side effects are possible with Rime?

Possible Side Effects and Safety Information

The official safety information for Rime (Cefpirome) classifies documented adverse reactions according to how frequently they occur in clinical use. These data are structured by regulatory authorities like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) to reflect the drug’s established risk profile.

Adverse Reaction Categories and Frequency

Adverse reactions are organized by the System-Organ-Class (SOC) they affect, including Gastrointestinal disorders, Hematologic changes, Hepatic changes, and Nervous system disorders.

Classification Examples of Documented Effects
Very Common Positive Coombs' test (a laboratory finding).
Common Diarrhea, rash, injection site reactions (e.g., phlebitis), and transient increases in liver enzymes (ALT, AST).
Uncommon Nausea, vomiting, headache, and increases in markers of kidney function.

Serious Adverse Reactions

Documented serious adverse reactions emphasized in official labeling include anaphylactic shock and severe, life-threatening allergic responses. Neurotoxicity, encompassing severe effects such as encephalopathy, seizures, and coma, is also recognized, particularly in patients with compromised kidney function who receive unadjusted doses. Additionally, Pseudomembranous colitis (C. difficile-associated diarrhea) is listed as a serious gastrointestinal concern.

Population-Specific Safety Considerations and Restrictions

Safety data highlight that the drug's primary route of elimination is the kidneys. Consequently, individuals with existing renal impairment or older adults (due to potentially reduced kidney function) require close monitoring. The regulatory profile explicitly notes that unadjusted dosing in this population increases the risk of serious neurological adverse reactions. Cefpirome is formally contraindicated in patients with a known history of severe hypersensitivity or allergic reaction to Cefpirome, other cephalosporins, or any other beta-Lactam antibiotic (such as penicillins) due to the documented risk of cross-allergic responses.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Rime overdose centers on the risk of severe neurotoxicity affecting the central nervous system. Documented clinical manifestations of overdose include a spectrum of neurological disturbances such as encephalopathy (ranging from confusion and hallucinations to stupor and coma), along with myoclonus (muscle jerks), neuromuscular excitability, and seizures (including nonconvulsive status epilepticus).

Overdose Severity and Risk Factors

This neurotoxicity is classified as potentially life-threatening and is associated with high systemic drug concentrations. Regulatory documents explicitly state that the risk is greatly increased in patients with renal impairment (Creatinine clearance le 60 mL/min) and in geriatric patients due to impaired drug clearance, which leads to drug accumulation.

Emergency Actions and Management

The mandated official emergency response is to seek immediate medical attention and contact emergency services upon the recognition of any severe neurological symptoms. Discontinuation of the drug is required. Management involves symptomatic and supportive treatment, and hemodialysis is documented as a procedure that may be utilized to aid in the removal of the compound from the body. No specific antidote is known.

Therapeutic Uses of Rime

What Rime Treats: Main Uses and Benefits

Rime (Cefpirome) is generally used to help manage serious or life-threatening bacterial infections, targeting conditions where symptoms may intensify temporarily and become quickly disruptive. This agent is relevant in contexts involving heightened systemic burden, primarily supporting the management of severe systemic infections, such as conditions involving episodic or fluctuating manifestations like septicaemia (bloodstream infection), severe pneumonia (lower respiratory tract infections), complicated pyelonephritis (kidney infection), and febrile neutropenia in immunocompromised patients.

This medication is applied in clinical settings that involve acute or unstable symptom patterns, addressing symptoms related to systemic imbalance, such as high fever and profound malaise. This strategy contributes to improved comfort and assists with maintaining functional stability during periods of acute disease. The focus is on providing supportive relief when symptoms interfere with routine activities.

“This medication is relevant when supportive symptom management is appropriate for acute systemic symptoms and conditions marked by increased physiological stress.”

Quick Fact: Symptomatic Focus
Is commonly used to help with: Symptoms related to systemic imbalance (high fever, malaise) and symptoms linked to organ-specific functional stress.
Benefit focus: Contributes to easing the overall symptom load and may assist with temporary stabilization when symptoms become temporarily overwhelming.

Regulatory References

  1. Australian Prescriber overview on Cefpirome

Eligibility and Restrictions for Use

Rime (Cefpirome) eligibility is defined by official regulatory documentation, primarily establishing which populations are contraindicated and which require conditional use or special caution.

Contraindications and Absolute Restrictions

Classification Population/Condition
Contraindicated Patients with known hypersensitivity or allergy to Cefpirome or any beta-Lactam antibacterial agents (e.g., penicillins, other cephalosporins).

Conditional Use and Special Populations

Classification Population/Condition
Restricted Use Impaired Renal Function (CrCL le 60 mL/min) is a major restriction; the official profile requires careful monitoring.
Not Recommended Pediatric patients (under 18 years) due to limited established safety and effectiveness data.
Special Caution Older adults require close monitoring of renal function. Pregnant and breastfeeding women should only use the medicine if the clinical benefit outweighs the unknown risk to the fetus or infant, as safety is not firmly established.

This framework ensures the medicine is administered only to eligible adult patients whose physiological status aligns with the drug's approved profile, focusing on renal clearance and allergy history as critical determinants for use.

What should I know about interactions with other medicines?

Rime Interactions with other medicines and products

Rimegepant, the active ingredient in Rime, interacts with certain other medicines and products primarily through shared metabolic pathways involving liver enzymes and drug transporters. The main mechanism is its metabolism by the CYP3A4 enzyme and its status as a substrate for the P-glycoprotein (P-gp) and BCRP transporters.

Contraindicated and Restricted Combinations

To manage potential interactions, specific combinations are either avoided or require strict timing. You should not take Rimegepant with the following product classes:

  • Strong CYP3A4 Inhibitors: Medications that strongly block the CYP3A4 enzyme (e.g., certain antifungals like itraconazole, or antibiotics like clarithromycin). Combining these significantly increases Rimegepant levels, potentially raising the risk of side effects.
  • Strong or Moderate CYP3A Inducers: Products that speed up the CYP3A4 enzyme (e.g., the antibiotic rifampin, or the herbal supplement St. John's Wort). These combinations can drastically lower Rimegepant levels, which may cause the medication to be ineffective.

Time-Spaced Dosing Requirements

Special attention is needed when combining Rimegepant with the following:

  • Moderate CYP3A4 Inhibitors (e.g., diltiazem, erythromycin, fluconazole).
  • Strong Inhibitors of P-gp (e.g., cyclosporine, quinidine).

If you take Rimegepant with any of these moderate inhibitors, a second dose of Rimegepant should be avoided within 48 hours of the co-administered drug. Always discuss all concurrent medicines, supplements, and herbal products with a healthcare professional to confirm safety.

Mechanism of Action

How Rime Works: Targeting Key Physiological Regulation

Rime exerts its pharmacodynamic effects by engaging two primary mechanistic domains: Receptor Signaling Modulation and Pathways of Physiological Hyperresponsiveness.


Receptor Signaling Modulation

This mechanism involves Rime's selective interaction with specific cell-surface mathbfreceptors, where it functions as either an mathbfantagonist or an mathbfagonist. This initial molecular binding modifies the cellular response to key circulating mathbfneurotransmitters or mathbfmediators. By initiating or suppressing these specific signaling events, Rime shapes subsequent molecular sequences and contributes to the overall mathbfregulation of targeted cellular activity.


Pathways of Physiological Hyperresponsiveness

Beyond receptor binding, Rime mathbfmodulates enzymatic and secondary messenger systems associated with intracellular pathways sensitive to activation. This influence on early molecular cascades reduces the activity resulting from high mediator concentration. This mechanism facilitates pathway mathbfadjustment and supports a state of modified signaling within the targeted biological systems.

Dosage and Administration Information

How to Use Rime (Cefpirome): Official Administration Guidelines

Rime is administered exclusively by the intravenous (IV) route, which requires professional supervision in a clinical setting. The medication is supplied as a sterile powder for injection and must be precisely reconstituted with a sterile diluent before use. The final solution is delivered either as a slow intravenous injection (bolus) over 3 to 5 minutes or a controlled IV infusion over 20 to 30 minutes.


Standard Dosing and Frequency

Usage Instruction Detail
Dose Range (Adult) 1 g to 2 g per dose (as Cefpirome base).
Standard Frequency Typically every 12 hours (Q12h).
Severe Case Frequency Every 8 hours (Q8h) may be used in specific critical care contexts.
Loading Dose An initial 1 g or 2 g dose precedes adjustments for maintenance dosing in renal impairment.

Renal Adjustment Requirement

A crucial component of the official usage instruction is the mandatory dose adjustment for patients with renal impairment. Following the initial loading dose, maintenance quantities and frequency must be modified according to the patient’s measured Creatinine Clearance (CC) levels. For example, lower doses are administered twice daily for a CC between 20 and 50 mL/min. No similar dosage adjustment is typically specified for hepatic impairment. This structure ensures adherence to standardized delivery protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rime

Evidence for Use in Severe Hospital Infections (Pneumonia and Septicaemia)

Research has explored Rime's use in research exploring severe, complicated infections often acquired in clinical settings, such as severe hospital-acquired pneumonia and septicaemia (bloodstream infections). The main body of evidence consists of Randomized Controlled Trials (RCTs) and various observational and controlled clinical studies. Research examined outcomes related to clinical response—measuring observed changes in the signs of infection—and bacteriological eradication (whether the harmful bacteria were cleared from the body or bloodstream). Survival rates following treatment were also monitored in these study populations.

Studies report various measurements of clinical response rates in adult populations receiving Rime for the study of these specific infections. Findings describe patterns observed in the studies regarding the clearance of bacteria and the evolution of infection symptoms. The evidence contributes to the broader evidence landscape by providing context on the drug's profile when studied against established, similar antibiotic treatments.

Evidence for Use in Compromised Immunity and Complex Infections

Research also explored Rime's use in conditions associated with heightened systemic stress, such as febrile neutropenia and complicated urinary tract infections (cUTI). Research for febrile neutropenia utilized Randomized Controlled Trials focused on immunocompromised adults. Studies monitored clinical response (resolution of fever and symptoms) and the need for changing to or adding other antibiotics. For cUTI, research focused on the clearance of bacteria from the urine and clinical measures of response. Evidence for this area is generally considered to be of Moderate level.

Understanding Long-Term Research and Follow-up Durations

The available clinical research on Rime typically focuses on the short-term outcomes that occur during and immediately after the required treatment course. Follow-up durations were limited in the majority of the main clinical trials, meaning that long-term effects are not fully established. There is limited information for long-term outcomes regarding the durability of the clinical response or the potential for symptom recurrence months or years later.

Synthesis of Research Gaps and Uncertainty

Data for other groups, such as pediatric or pregnant populations, remain insufficient in the main regulatory evidence landscape. Furthermore, comparative evidence is lacking for some of the most recently developed antibiotics, and evidence remains limited regarding the effects of Rime on certain highly resistant organisms that have emerged in hospitals more recently.

Key Studies & References

  1. Antimicrobial Agents: Cefpirome (NIH MedlinePlus/NLM Entry)
  2. Cefpirome Sulfate: An Overview for Australian Prescribers (Australian Prescriber)
  3. Pharmacokinetic and Pharmacodynamic Studies of Cefpirome in Critically Ill Patients (PubMed Indexed Research)

Frequently Asked Questions (FAQ)

Common questions about Rime (FAQ)


Q: How is Rime different from similar medicines used for the same condition?

A: Rime contains the active ingredient Cefpirome, which is classified as a fourth-generation cephalosporin. Official research has explored the drug's activity profile, noting that it may exhibit an enhanced resilience against certain bacterial defense mechanisms, known as beta-Lactamases, when compared to some older cephalosporin antibiotics.


Q: How long does it typically take for Rime to show an effect?

A: The official product information describes the effect of Rime as initiating soon after administration, consistent with its intravenous delivery. Clinical administration schedules often reflect this established duration of effect, with doses typically provided at intervals to maintain the drug’s presence in the body.


Q: Are there any food or drinks that should be avoided while using Rime?

A: Official drug summaries state that the use of Rime does not depend on food timings, and there are no specific food or drink restrictions mentioned in the administration guidelines. Because Rime is given intravenously in a clinical setting, it bypasses the digestive system where food interactions typically occur.


Q: Can Rime interact with alcohol?

A: Official safety data currently indicate that the interaction between Rime’s active ingredient and alcohol is either unknown or has not been established. Concerns regarding the combination of Rime and alcohol should be directed to a healthcare professional.


Q: Can Rime affect sleep patterns?

A: The official safety profile documents adverse effects that may impact the nervous system, such as headache and, rarely, severe neurotoxicity. However, there is no consistent evidence in the established documentation to characterize the drug's common effects on general sleep patterns, such as insomnia or vivid dreams.


Q: Are the side effects of Rime temporary?

A: Most common adverse reactions are typically noted to resolve after the course of treatment is completed. Individuals are advised to contact their healthcare professional if any severe or worsening side effects occur. The official information lists the frequency of side effects like rash, diarrhea, or injection site reactions.


Q: Is it safe to suddenly stop taking Rime?

A: Rime is an antibiotic intended to be used for the full duration prescribed by a healthcare professional. Discontinuing any antibiotic course before completion is associated with a risk of recurrence or the development of bacterial resistance, according to established medical principles.


Q: What is the difference between Rime and [Name of Common Competitor Drug]?

A: Rime contains the active ingredient Cefpirome, which is classified as a fourth-generation cephalosporin. Official research has explored the drug's activity profile, noting that it may exhibit an enhanced resilience against certain bacterial defense mechanisms, known as beta-Lactamases, when compared to some older cephalosporin antibiotics.


Q: Does Rime start working immediately?

A: The official product information describes the effect of Rime as initiating soon after administration, consistent with its intravenous delivery. The observation of clinical improvement or full effect takes place over the course of the treatment.


Q: What happens if I miss a dose of Rime?

A: Since Rime must be administered by a qualified healthcare professional in a hospital or clinical setting, the risk of a dose being missed is exceptionally low. If there is any concern about the timing of a scheduled dose, the patient or caregiver is advised to contact the healthcare professional responsible for administration.


Q: Is it normal to feel a mild headache when starting Rime?

A: Headache is listed in the official safety information as an uncommon side effect, meaning it is not frequently observed in patients receiving the drug. The most common effects include injection site reactions, rash, and diarrhea. Any new or persistent symptoms should be discussed with a healthcare team.


Q: Can Rime affect mood or cause anxiety?

A: The official safety profile highlights the potential for rare, severe nervous system effects, particularly in patients with kidney problems, which can include confusion. However, common or generalized effects on mood or anxiety are not consistently documented within the drug's established safety risk profile.


Q: Does Rime cause drowsiness or affect alertness?

A: Official safety documents indicate that Rime may potentially cause adverse reactions such as dizziness, confusion, or altered consciousness. Official documentation notes that activities requiring full mental focus, such as driving or operating machinery, may require caution if these adverse effects are experienced.


Q: Are there studies comparing Rime across different patient demographics?

A: Official regulatory evidence indicates that studies primarily focus on adult patient populations. Data remains limited or insufficient for specific groups, such as pediatric patients and pregnant or breastfeeding women. This results in restrictions or the need for special caution when Rime is considered for these populations.


Q: Why are there warnings about driving while taking Rime?

A: Warnings concerning driving or using machinery are included because the drug’s official safety profile documents potential adverse effects like altered consciousness, dizziness, or confusion. It is noted that patients may need to exercise caution if these symptoms occur.


Q: How should Rime be disposed of when no longer needed?

A: Unused or expired Rime should never be disposed of in the household trash, poured down a sink, or flushed down a toilet. Disposal must follow strict local pharmaceutical waste regulations, which often require returning the product to a hospital or designated drug take-back program.


Q: What does official research say about the effectiveness of Rime?

A: Research has explored Rime’s effectiveness in treating severe infections, primarily focusing on outcomes such as clinical response and whether the harmful bacteria were successfully cleared from the body (bacteriological eradication). This evidence contributes to the drug’s use in treating specific susceptible bacterial infections.


Q: What should I know about taking Rime if I have other medical conditions?

A: Official guidelines emphasize that patients with impaired renal function (kidney problems) require special attention and close monitoring because the drug is primarily eliminated through the kidneys. Also, having a history of severe allergy to beta-Lactam antibiotics is an absolute restriction for using Rime.

How should Rime be stored and disposed of?

How to Store and Dispose of Rime? (Cefpirome)

The storage and disposal of Rime (Cefpirome) must strictly adhere to regulatory requirements to maintain product stability and safety.


Storage and Handling

The unreconstituted sterile powder must be stored under refrigerated conditions, typically between 2°C and 8°C. The container must be kept tightly closed in the original package and protected from both moisture and light. The medicine must always be stored out of the sight and reach of children.

Because the solution is chemically unstable, the product should be used immediately after reconstitution. The prepared solution must not be frozen.


Disposal Requirements

Unused or expired Rime and related materials must not be disposed of in household trash or poured down wastewater systems. Disposal must strictly follow local pharmaceutical waste regulations, ensuring the product is returned or handled through a designated collection system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rime found in:

A-Z Index: